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Abstract
Cancer is the second leading cause of death worldwide and the lack of 
alternative therapies has kept patients dependent on classic chemo-
therapy. The most occurring form of cancer amongst women is breast 
cancer and the triple negative cell subtype (TNBC) is responsible for a 
high metastatic and mortality rate, as it presents molecular and genet-
ic shifts, lacks speciﬁc targeting and responds poorly to existing thera-
pies. Recent studies have provided convincing evidence that the ther-
apeutic outcome of chemotherapy may be aﬀected by the expression 
and activity of receptor tyrosine kinases and their phosphatase path-
ways (MAPK/ERK, PI3/AKT, among others). These proteins are impli-
cated in mechanisms of cell survival, drug resistance and Epitheli-
al-Mesenchymal Transition (EMT), and are therefore key targets for 
TNBC cancer cell subtype. However, many inhibitors developed for 
these targets have not succeeded at a clinical level and present low 
solubility.
As a result of the pronounced decline in productivity experienced by 
drug discovery eﬀorts in the last years, novel approaches to the 
rational design of new drugs are now being pursued. A potential solu-
tion might be the use of natural or synthetic peptides and peptidomi-
metics targeting protein-protein interactions essential for signaling 
networks function. The combination of several bioinformatic 
approaches (docking, virtual screening, pharmacophore models, 
among others) allows the use of the vast amount of existing informa-
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tion on available compounds and protein-protein interactions in struc-
tural databases.
In this study we designed a procedure for small peptidomimetics 
structure-based rational drug design capable of blocking the active 
sites of SNAiL1, a protein that has been suggested as a potent 
repressor of E-cadherin expression and consequently, as an inducer 
of EMT transition in TNBCs. A random library was created using a 
composite approach for drug-like compound identiﬁcation from the 
PubChem and Development Therapeutics NCI/NIH compound data-
bases, which combined structure-based virtual screening (known 
motifs of peptide structures within proteins and small molecules) and 
Z-score comparison. Docking studies were performed to map the 
polypeptides activity and stability: (1) point alteration studies using 
non-natural aminoacids for helical stability over a wider range (since 
linear peptides adopt many conﬁrmations in aqueous solution) using 
Ramachandran plot dihedral angles estimation; (2) quantitative struc-
ture-activity relationships (QSAR) using radical modiﬁcation chemical 
studies and (3) umbrella sampling for dissociations studies. The pepti-
domimetic SNAiL1 model created suggested at least two radical mod-
iﬁcations for a strong inhibition.
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